Cabozantinib and IL-27 combinatorial therapy for bone-metastatic prostate cancer.

ABSTRACT: Introduction: Prostate cancer is the second leading cause of cancer-related death among American men. Prostate tumor cells exhibit significant tropism for the bone and once metastasis occurs, survival rates fall significantly. Current treatment options are not curative and focus on symptom management. Immunotherapies are rapidly emerging as a possible therapeutic option for a variety of cancers including prostate cancer, however, variable patient response remains a concern. Chemotherapies, like cabozantinib, can have immune-priming effects which sensitize tumors to immunotherapies. Additionally, lower doses of chemotherapy can be used in this context which can reduce patient side effects. We hypothesized that a combination of chemotherapy (cabozantinib) and immunotherapy [Interleuki

SUBMITTER: Kumar S 

PROVIDER: S-EPMC10568464 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature